EC Number   |
Natural Substrates |
|---|
    1.14.15.6 | (20R,22R)-20,22-dihydroxy-cholesterol + 2 reduced adrenodoxin + O2 |
- |
| 1.14.15.6 | (22R)-22-hydroxycholesterol + 2 reduced adrenodoxin + O2 |
- |
| 1.14.15.6 | cholesterol + 2 reduced adrenodoxin + O2 |
- |
| 1.14.15.6 | cholesterol + 6 reduced adrenodoxin + 3 O2 |
- |
| 1.14.15.6 | cholesterol + reduced adrenal ferredoxin + O2 |
- |
| 1.14.15.6 | more |
cytochrome P450scc metabolizes vitamin D3 to 20-hydroxyvitamin D3 and 20,23-dihydroxyvitamin D3, as well as 1-hydroxyvitamin D3 to 1alpha,20-dihydroxyvitamin D3. It also cleaves the side chain of 7-dehydrocholesterol producing 7-dehydropregnenolone, which can be transformed to 20-hydroxy-7-dehydropregnenolone |
| 1.14.15.6 | cholesterol + reduced adrenal ferredoxin + O2 |
first and rate-limiting enzyme in adrenal steroidogenesis |
| 1.14.15.6 | cholesterol + 6 reduced adrenodoxin + 3 O2 |
first step in biosynthesis of all steroid hormones |
| 1.14.15.6 | more |
involved in control of pain mechanisms |
| 1.14.15.6 | more |
leptin interferes with adrenocorticotropin/cAMP signaling, possibly through a janus kinase 2-phosphatidylinositol 3-kinase/akt-phosphodiesterase 3-cAMP pathway, to down-regulate cholesterol side-chain cleavage cytochrome P450 enzyme in human adrenocortical NCI-H295 cell line, mechanism, overview |
